Practical Diagnosis of Hematologic Disorders

Vol 2

Malignant Disorders
Authors

Carl R Kjeldsberg, MD
Professor of Pathology, University of Utah Health Sciences Center
Chairman of the Board, ARUP Laboratories, Inc

Sherrie L Perkins, MD, PhD
Professor of Pathology, University of Utah Health Sciences Center
Chief Medical Officer, Director of Laboratories, Medical Director of Hematopathology, ARUP Laboratories, Inc

John Anastasi, MD
Associate Professor, Associate Director Hematopathology
Department of Pathology
University of Chicago Medical Center

Daniel A Arber, MD
Professor and Associate Chair of Pathology for Clinical Services
Stanford University

David W Bahler, MD, PhD
Associate Professor of Pathology, University of Utah
Director, Hematologic Flow Cytometry Laboratory, ARUP Laboratories, Inc

Robert C Blaylock, MD
Professor of Pathology, Medical Director of University Hospital Transfusion Services and ARUP Blood Services
Medical Director of the Immunohematology Reference Laboratory, ARUP Laboratories, Inc
Co-Director of University Hospital Clinical Laboratories

Kojo S J Elenitoba-Johnson, MD
Professor of Pathology, Director of Division of Translational Research
Director of Molecular Diagnostics Laboratory
Director, Molecular Genetic Pathology Program
University of Michigan

Kathryn Foucar, MD
Professor of Pathology, Vice Chair for Clinical Affairs
University of New Mexico Health Sciences Center and TriCore Reference Laboratories

Amy Heerema-McKenney, MD
Clinical Assistant Professor, Department of Pathology
Stanford University

Megan S Lim, MD, PhD
Associate Professor of Pathology, Director of Hematopathology
Director, Hematopathology Fellowship Training Program
University of Michigan

Robert W McKenna, MD
Professor and Vice Chair for Academic Affairs
Senior Consultant in Hematopathology, Department of Laboratory Medicine and Pathology
Richard D Brunning Professor of Laboratory Medicine and Pathology
University of Minnesota

LoAnn C Peterson, MD
Paul E Steiner Research Professor of Pathology, Feinberg Medical School
Northwestern University, Northwestern Memorial Hospital

George M Rodgers, MD, PhD
Professor of Medicine and Pathology, University of Utah Health Sciences Center
Medical Director, Coagulation Laboratory, ARUP Laboratories, Inc

Mohamed E Salama, MD
Assistant Professor of Pathology, University of Utah Health Sciences Center
Assistant Medical Director, Hematopathology, ARUP Laboratories, Inc

James W Vardiman, MD
Professor of Pathology
University of Chicago Medical Center
Publishing Team

Erik Tanck (production/designer)
Joshua Weikersheimer (publishing direction)

Notice
Trade names and equipment and supplies described herein are included as suggestions only. In no way does their inclusion constitute an endorsement or preferences by the American Society for Clinical Pathology. The ASCP did not test the equipment, supplies, or procedures and, therefore, urges all readers to read and follow all manufacturers' instructions and package insert warnings concerning the proper and safe use of products.
Vol 2 Malignant Disorders

Preface  xiii

Acknowledgments  xiv

Part IX  Myeloid Neoplasms

Myeloproliferative Neoplasms

35. Chronic Myelogenous Leukemia, BCR-ABL1+  419
   John Anastasi, MD
   James Vardiman, MD

36. Chronic Neutrophilic Leukemia  443
   John Anastasi, MD
   James Vardiman, MD

37. Polycythemia Vera  449
   John Anastasi, MD
   James Vardiman, MD

38. Primary Myelofibrosis  467
   John Anastasi, MD
   James Vardiman, MD

39. Essential Thrombocythemia  487
   John Anastasi, MD
   James Vardiman, MD

40. Chronic Eosinophilic Leukemia, NOS  501
   Sherrie Perkins, MD, PhD
   Mohamed Salama, MD
   James Vardiman, MD

41. Mastocytosis  509
   Megan S Lim, MD, PhD

42. Myeloproliferative Neoplasms, Unclassifiable  521
   James Vardiman, MD
   John Anastasi, MD
MYELOID AND LYMPHOID NEOPLASMS WITH EOSINOPHILIA AND ABNORMALITIES OF PDGFRA, PDGFRB OR FGFR1

43. Myeloid and Lymphoid Neoplasms With Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1
Mohamed Salama, MD
Sherrie Perkins, MD, PhD

44. Myelodysplastic/Myloloproliferative Neoplasms 535
Sherrie Perkins, MD, PhD
James Vardiman, MD

MYELODYSTAPTIC SYNDROMERES

45. Myelodysplastic Syndromes 547
Sherrie L Perkins, MD, PhD
Robert W McKenna, MD

Part X Acute Myeloid Leukemias

ACUTE MYELOID LEUKEMIA AND RELATED PRECURSOR NEOPLASMS

46. Acute Myeloid Leukemia With Recurrent Genetic Abnormalities 585
Amy Heerema-McKenney, MD
Daniel A. Arber, MD

47. Acute Myeloid Leukemia With Myelodysplasia-Related Changes and Therapy-Related Myeloid Neoplasms 615
Amy Heerema-McKenney, MD
Daniel A Arber, MD

48. Acute Myeloid Leukemia, NOS 621
Amy Heerema-McKenney, MD
Daniel A Arber, MD

49. Myeloid Sarcoma 633
Amy Heerema-McKenney, MD
Daniel A Arber, MD

50. Myeloid Proliferations Related to Down Syndrome 639
Amy Heerema-McKenney, MD
Daniel A Arber, MD

51. Blastic Plasmacytoid Dendritic Cell Neoplasm 645
Amy Heerema-McKenney, MD
Daniel A Arber, MD
52. Acute Leukemias of Ambiguous Lineage 653
   Amy Heerema-McKenney, MD
   Daniel A Arber, MD

Part XI  Lymphoid Neoplasms

53. Introduction to Non-Hodgkin Lymphoma 661
   Kojo SJ Elenitoba-Johnson, MD
   Megan S Lim, MD, PhD
   Carl Kjeldsberg, MD

Part XII  Precursor Lymphoid Neoplasms

54. Precursor Lymphoid Neoplasms 691
   Sherrie L Perkins MD, PhD
   Robert McKenna, MD

Part XIII  Mature B-Cell, T-Cell and Histiocytic Neoplasms

Mature B-Cell Neoplasms

55. Mature B-Cell Neoplasms With Leukemic Manifestations 723
   LoAnn Peterson, MD

56. Mature B-Cell Neoplasms With Plasma Cell or Plasmacytoid Differentiation 747
   LoAnn Peterson, MD

57. Mature B-Cell Neoplasms With Primary Tissue Manifestations 769
   Kojo S J Elenitoba-Johnson, MD
   Megan S Lim, MD
   Carl Kjeldsberg, MD

Mature T-Cell and NK-Cell Neoplasms

58. Mature T-Cell and NK-Cell Neoplasms 805
   Kojo S J Elenitoba-Johnson, MD
   Megan S Lim, MD
   Carl Kjeldsberg, MD
HODGKIN LYMPHOMA

59. Hodgkin Lymphoma 835
   Carl Kjeldsberg, MD
   Kojo S J Elenitoba-Johnson, MD

HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS

60. Histiocytic and Dendritic Cell Neoplasms 853
   Megan S Lim, MD, PhD

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS

61. Post-Transplant Lymphoproliferative Disorders 865
   Megan S Lim, MD, PhD

Part XIV  Special Techniques

62. Molecular Techniques in the Diagnosis of Hematologic Malignancies 879
   Kojo S J Elenitoba-Johnson, MD

63. Flow Cytometric Analysis 899
   David Bahler, MD, PhD

Appendix

Appendix: Hematology Reference Values 919

Index  p index 2.1 and following
### List of Tables

**Ch 35. Chronic Myelogenous Leukemia, BCR-ABL1+**
- **t35.1** Features of Chronic Myelogenous Leukemia BCR-ABL1+, Chronic Phase  424
- **t35.2** WHO Criteria for Chronic Myelogeneous Leukemia, Accelerated Phase  428
- **t35.3** CML, Blast Phase  428
- **t35.4** Distinguishing Features Among the Chronic Myeloid Leukemias  436
- **t35.5** Summary of Features of Chronic Neutrophilic Leukemia (CNL)  437

**Ch 37. Polycythemia Vera**
- **t37.1** Stages and Associated Features in Polycythemia Vera  449
- **t37.2** Classification of Polycythemia  452
- **t37.3** WHO Recommended Criteria for the Diagnosis of Polycythemia Vera  456
- **t37.4** Comparison of Findings in Polycythemia Vera and Secondary Erythrocytosis  457

**Ch 38. Primary Myelofibrosis**
- **t38.1** Causes of Bone Marrow Fibrosis  468
- **t38.2** Major Clinical and Laboratory Features in PMF  470
- **t38.3** WHO Diagnostic Criteria for Primary Myelofibrosis  471
- **t38.4** Myeloid Disorders With Myelofibrosis  482
- **t38.5** Comparison of Usual Findings in Polycythemia Vera-Polycythemec Phase, PMF-Prefibrotic Stage, and Essential Thrombocytethia  482

**Ch 39. Essential Thrombocythemia**
- **t39.1** Causes of Marked Thrombocytosis  487
- **t39.2** Features Helpful in Distinguishing Essential Thrombocythemia and Secondary Thrombocytosis  489
- **t39.4** Morphologic Features of ET  491
- **t39.5** Comparison of Features of Essential Thrombocythemia With Other Chronic Myeloproliferative Disorders  495

**Ch 40. Chronic Eosinophilic Leukemia, NOS**
- **t40.1** Diagnostic Criteria of Chronic Eosinophilic Leukemia, NOS  502
- **t40.2** Systemic Involvement by Chronic Eosinophilic Leukemia, NOS  503
- **t40.3** Differential Diagnostic Consideration for Persistent Eosinophilia  506

**Ch 41. Mastocytosis**
- **t41.1** Classification of Mast Cell Disease
  (Adapted From World Health Organization Criteria)  510
- **t41.2** Major and Minor Diagnostic Criteria for Systemic Mastocytosis  514
- **t41.3** Comparison of Immunophenotypes of Mast Cells and Closely Related Cell Types  519

**Ch 42. Myeloproliferative Neoplasms, Unclassifiable**
- **t42.1** Situations in Which a Diagnosis of Myeloproliferative Neoplasm-Unclassifiable Can Be Considered  522

**Ch 43. Myeloid and Lymphoid Neoplasms With Eosinophilia and Abnormalities of PDGFR, PDGFRB or FGFR1**
- **t43.1** Fusion Partners of PDGFRB and Related Cytogenetic Defects Occurring in Myeloid Neoplasms Presenting With Eosinophilia  530
- **t43.2** FGFR1 Gene Fusion Partners  533
Ch 44. Myelodysplastic/Myeloproliferative Neoplasms

- **t44.1** Features Distinguishing Myelodysplastic Syndrome (MDS) from Myeloproliferative Neoplasms (MPN)
- **t44.2** WHO Classification of Myelodysplastic/Myeloproliferative Neoplasms
- **t44.3** Diagnostic Criteria for Chronic Myelomonocytic Leukemia
- **t44.4** Diagnostic Criteria for Atypical Chronic Myeloid Leukemia, *BCR-ABL1*—(aCML)
- **t44.5** Comparison of Chronic Myelogenous Leukemia (CML) and Atypical Chronic Myelogenous Leukemia (aCML)
- **t44.6** Diagnostic Criteria of Juvenile Myelomonocytic Leukemia
- **t44.7** Diagnostic Criteria for Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (MDS/MPN, U)

Ch 45. Myelodysplastic Syndromes

- **t45.1** International Prognostic Scoring System (IPSS) Thresholds for Cytopenias in the Diagnosis of Myelodysplastic Syndromes
- **t45.2** WHO Classification of MDS
- **t45.3** Hematologic Findings in Myelodysplastic Syndromes
- **t45.4** Morphologic Abnormalities in Myelodysplastic Syndromes
- **t45.5** Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes
- **t45.6** International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes
- **t45.7** Chromosome Abnormalities Seen in MDS and Candidate Genes Affected
- **t45.8** Immunophenotypic Abnormalities Observed in Myelodysplastic Syndromes
- **t45.9** Peripheral Blood and Bone Marrow Findings in Myelodysplastic Syndromes
- **t45.10** Refractory Anemia (RA)
- **t45.11** Refractory Anemia With Ringed Sideroblasts (RARS)
- **t45.12** Refractory Cytopenia With Multilineage Dysplasia (RCMD)
- **t45.13** Refractory Anemia With Excess Blasts (RAEB)
- **t45.14** Myelodysplastic Syndrome With Isolated del(5q)
- **t45.15** Pediatric MDS
- **t45.16** WHO Minimal Diagnostic Criteria for Refractory Cytopenia of Childhood
- **t45.17** Comparison of Morphological Criteria of Hypoplastic Refractory Cytopenia of Childhood and Aplastic Anemia
- **t45.18** Differential Diagnostic Considerations in Myelodysplastic Syndromes
- **t45.19** Survival, Prognosis and Evolution to AML in Adult Patients with MDS
- **t45.20** Indicators of Good and Poor Prognosis in Myelodysplastic Syndromes

Ch 46. Acute Myeloid Leukemia (AML) With Recurrent Genetic Abnormalities

- **t46.1** French-American-British (FAB) Classification Morphologic Categories of AML
- **t46.2** WHO 2008 Classification of Acute Myeloid Leukemia
- **t46.3** Cytologic Features of Blasts in Acute Myeloid and Acute Lymphoblastic Leukemias
- **t46.4** Cytochemical Stains and Their Utility
- **t46.5** Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research Composite Prognostic Index for Adult AML (age <60)
- **t46.6** Common Variant Translocations of APL
- **t46.7** Common *MLL* Fusion Transcripts in AML

Ch 47. AML With Myelodysplasia-Related Changes and Therapy-Related Myeloid Neoplasms

- **t47.1** Criteria for Diagnosis of AML With Myelodysplasia-Related Changes

Ch 48. AML, NOS

- **t48.1** Differential Diagnosis of Acute Basophilic Leukemia (ABL)

Ch 49. Myeloid Sarcoma

- **t49.1** Characteristics of Adult vs Pediatric Myeloid Sarcoma
Ch 51. Blastic Plasmacytoid Dendritic Cell Neoplasm

- **t51.1** Immunophenotypic Overlap Between Blastic Plasmacytoid Dendritic Cell Neoplasm and Cases of Cutaneous Involvement by Acute Myeloid Leukemia
- **t51.2** Distinguishing Blastic Plasmacytoid Dendritic Cell Neoplasm From CD56+ True NK-Cell, NK/T-Cell and γδ T-Cell Lymphoma/Leukemias

Ch 53. Introduction to Non-Hodgkin Lymphoma

- **t53.1** Cytogenetic and Molecular Abnormalities in Non-Hodgkin Lymphoma
- **t53.2** Predisposing Conditions and Factors in the Development of Non-Hodgkin Lymphoma
- **t53.3** Comparison of Non-Hodgkin and Hodgkin Lymphomas
- **t53.4** Stages of Lymphoma
- **t53.5** National Cancer Institute Modified Staging for Intermediate- and High-Grade Lymphomas
- **t53.6** Staging Procedures for Non-Hodgkin Lymphoma
- **t53.7** Principles of Classification of Non-Hodgkin Lymphoma
- **t53.8** Mature Neoplasms
- **t53.9** Major Antibodies Used in Immunophenotyping of Malignant Lymphomas in Paraffin Sections
- **t53.10** Application of Immunophenotypic Analysis
- **t53.11** Undifferentiated Large Neoplasm Antibody Panel for Paraffin Sections
- **t53.12** Immunophenotyping of Non-Hodgkin and Hodgkin Lymphomas in Paraffin Sections
- **t53.13** Comparison of Non-Hodgkin Lymphoma Features in Children and Adults
- **t53.14** Classification of Non-Hodgkin Lymphoma in Children
- **t53.15** Comparison of Morphologic and Immunophenotypic Features in Childhood Non-Hodgkin Lymphomas
- **t53.16** Causes of Lymph Node Enlargement Simulating Malignant Lymphoma
- **t53.17** International Prognostic Index of Parameters and Relative Risk
- **t53.18** International Prognostic Index: The International Index and Age-Adjusted Index
- **t53.19** Histopathology and Prognosis in Non-Hodgkin Lymphomas
- **t53.20** Cellular Prognostic in Non-Hodgkin Lymphomas
- **t53.21** Checklist for the Reporting of Lymphoid Neoplasms
- **t53.22** New Therapeutic Agents in Malignant Lymphoma

Ch 54. Precursor Lymphoid Neoplasms

- **t54.1** WHO Classification of Acute Lymphoblastic Leukemia/Lymphoma
- **t54.2** Frequency of Clinical and Laboratory Findings at Diagnosis in Children and Adults with ALL
- **t54.3** Characteristic Clinical Features of Precursor T-ALL
- **t54.4** Distribution of White Cell Counts at Diagnosis
- **t54.5** FAB Morphologic Classification of Lymphoblasts
- **t54.6** Common Antigen Expression Patterns of Acute Lymphoblastic Leukemias/ Lymphoblastic Lymphomas
- **t54.7** Distribution of Immunophenotypic Subtypes in Acute Lymphoblastic Leukemia
- **t54.8** Correlation of Prognosis with Bone Marrow Cytogenetic Findings in ALL
- **t54.9** Cytogenetic Translocations Associated With Specific Molecular Genetic Abnormalities in ALL
- **t54.10** Most Significant Prognostic Indicators in Pediatric ALL
- **t54.11** Adverse Prognostic Factors in Adult and Pediatric ALL

Ch 55. Mature B-Cell Neoplasms With Leukemic Manifestations

- **t55.1** Mature B-Cell Neoplasms With Leukemic Manifestations
- **t55.2** Rai Clinical Staging System for Chronic Lymphocytic Leukemia
- **t55.3** Binet Staging System for Chronic Lymphocytic Leukemia
- **t55.4** Typical Phenotypes of B-Cell Chronic Lymphoid Leukemias and Lymphomas
Practical Diagnosis of Hematologic Disorders

Ch 56. Mature B-Cell Neoplasms With Plasma Cell or Plasmacytoid Differentiation
  t56.1 Mature B-Cell Neoplasms With Plasma Cell or Plasmacytoid Differentiation 747
  t56.2 Monoclonal Immunoglobulins in Mature B-Cell Neoplasms With Plasma Cell Differentiation 748
  t56.3 Approximate Incidence of Monoclonal Gammopathies in the United States 749
  t56.4 Diagnostic Criteria for Monoclonal Gammopathy of Undetermined Significance 749
  t56.5 Course of 241 Patients With Monoclonal Gammopathy of Undetermined Significance 750
  t56.6 Diagnostic Criteria for Plasma Cell Myeloma 751

Ch 57. Mature B-Cell Neoplasms With Primary Tissue Manifestations
  t57.1 Mature B-Cell Neoplasms With Primary Tissue Manifestations 769
  t57.2 Small Lymphocytic B-Cell Neoplasms: Characteristic Morphologic Features 770
  t57.3 Small Lymphocytic B-Cell Neoplasms: Immunophenotypic Features 770
  t57.4 Useful Features in the Differential Diagnosis of Mediastinal Lymphomas 794

Ch 58. Mature T-Cell and NK-Cell Neoplasms
  t58.1 Mature T-Cell and NK-Cell Neoplasms 805
  t58.2 Differential Diagnosis of Neoplasms Expressing T-Cell and NK-Cell Markers With Frequent Leukemic Presentation 810
  t58.3 Differential Diagnosis of Neoplasms Expressing T-Cell and NK-Cell Markers With Frequent Cutaneous Involvement 825
  t58.4 Differential Diagnosis of Nodal Peripheral T-Cell Lymphoma, Not Otherwise Specified 827
  t58.5 Characteristics of Variant ALK Translocations 832

Ch 59. Hodgkin Lymphoma
  t59.1 Staging Procedures in Hodgkin Lymphoma 837
  t59.2 The Cotswald Modification of the Ann Arbor Staging Classification for Hodgkin Lymphoma 837
  t59.3 World Health Organization (WHO) Classification of Hodgkin Lymphoma 837
  t59.4 Immunophenotype Features of RS Cells and L&H Cells 839
  t59.5 Differential Diagnosis of Hodgkin Lymphoma 839
  t59.6 Immunophenotypic Distinction of Hodgkin Lymphoma From Non-Hodgkin Lymphoma 851

Ch 60. Histiocytic and Dendritic Cell Neoplasms
  t60.1 Immunophenotypic Features Useful in the Distinction of Macrophages, Langerhans Cells, Dendritic Cells and Lymphocytes 854
  t60.2 Clinical Variants of Langerhans Cell Histiocytosis 856
  t60.3 Differential Diagnosis of Langerhans Cell Histiocytosis 860

Ch 61. Post-Transplant Lymphoproliferative Disorders
  t61.1 Comparison of Post-Transplant Lymphoproliferative Disorders Occurring in Solid Organ and Bone Marrow Transplant Patients 866
  t61.2 Evaluation for Diagnosis of PTLDs 867
  t61.3 General Categories of Post-Transplantation Lymphoproliferative Disorders 868

Ch 62. Molecular Techniques in the Diagnosis of Hematologic Malignancies
  t62.1 Comparison of Molecular Methods Used in Diagnostic Hematopathology 880
  t62.2 Genetic Alterations in Hematologic Malignancies 881–882

Ch 63. Flow Cytometric Analysis
  t63.1 Fluorochromes Often Used With 488-nm Wavelength Excitation 900
  t63.2 Common Hematopoietic Cell Antigens Evaluated With Flow Immunophenotyping 903
  t63.3 Common Antigens Used to Assess Acute Leukemia Blast Lineage by Flow Cytometry 907
  t63.4 Characteristic Phenotypic Features Associated with Specific Acute Leukemias 907
  t63.5 Typical Immunophenotypes of Mature B-Cell Neoplasms 910
  t63.6 Phenotypic Features Associated With Specific Mature T-Cell Neoplasms 913
The goal of this book, beginning with the first edition in 1989, has been to provide an up-to-date, concise source of guidelines to the selection, use and interpretation of laboratory tests, while at the same time providing an overview of the pathogenesis and clinical features of the most common hematologic disorders.

Though the size and scope of this book have increased considerably, keeping pace with the expansion of the knowledge and diagnostic complexity in hematopathology, the focus on providing practical information has not changed. Each chapter follows a practical format to make finding specific information easy. This fifth edition contains substantial new information, particularly with regard to molecular modalities and utilization of ancillary testing in the diagnosis of hematologic disorders. The new edition uses the framework of the 2008 WHO classification for malignancies, and provides up-to-date diagnostic approaches, correct usage of laboratory testing, and algorithms for diagnosis of both benign and malignant disorders.

We hope that this newest edition will be an even more valuable tool and resource for a broad audience, including pathologists, residents and fellows in pathology and medicine, hematologists/oncologists, internists, pediatricians, medical students and medical technologists, as well as for those preparing for board examinations in pathology and internal medicine.

We welcome your comments or suggestions for future editions and trust that this book will provide the quality information and education you’ve come to expect.
We wish to express our appreciation to Joshua Weikersheimer of the ASCP Press, for his assistance in all aspects of publication, and to Susan Flinders for administrative assistance.

We want to also thank our colleagues in the Department of Pathology at the University of Utah, and the staff at ARUP Laboratories for their support. Present and former hematology fellows have provided much inspiration.

Most of all, we are grateful for the support and love from our families, Gillean, Tanya, Kristina, Don, Rachel and Jessica.